Focal adhesion kinase

References

• van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, Reyners AK. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol 2012; 84:224 - 42; http://dx.doi.org/10.1016/j.critrevonc.2012.03.006; PMID: 22525643
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220 - 31; http://dx.doi.org/10.1016/j.ccr.2009.01.027; PMID: 19249680
   PubMed Web of Science ®Google Scholar
• Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001; 294:1708 - 12; http://dx.doi.org/10.1126/science.1064829; PMID: 11721053
   PubMed Web of Science ®Google Scholar
• Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of FAK expression in human neoplasia. Histol Histopathol 2008; 23:629 - 50; PMID: 18283648
   PubMed Web of Science ®Google Scholar
• Mon NN, Ito S, Senga T, Hamaguchi M. FAK signaling in neoplastic disorders: a linkage between inflammation and cancer. Ann N Y Acad Sci 2006; 1086:199 - 212; http://dx.doi.org/10.1196/annals.1377.019; PMID: 17185517
   PubMed Web of Science ®Google Scholar
• Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000; 19:5606 - 13; http://dx.doi.org/10.1038/sj.onc.1203877; PMID: 11114741
   PubMed Web of Science ®Google Scholar
• McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005; 5:505 - 15; http://dx.doi.org/10.1038/nrc1647; PMID: 16069815
   PubMed Web of Science ®Google Scholar
• Angelucci A, Bologna M. Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family. Curr Pharm Des 2007; 13:2129 - 45; http://dx.doi.org/10.2174/138161207781039643; PMID: 17627545
   PubMed Web of Science ®Google Scholar
• Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23:8065 - 77; http://dx.doi.org/10.1038/sj.onc.1207959; PMID: 15361855
   PubMed Web of Science ®Google Scholar
• Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004; 165:1087 - 95; http://dx.doi.org/10.1016/S0002-9440(10)63370-6; PMID: 15466376
   PubMed Web of Science ®Google Scholar
• Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001; 91:534 - 40; http://dx.doi.org/10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.0.CO;2-T; PMID: 11169935
   PubMed Web of Science ®Google Scholar
• Hauptmann S, Denkert C, Koch I, Petersen S, Schlüns K, Reles A, Dietel M, Petersen I. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 2002; 33:632 - 41; http://dx.doi.org/10.1053/hupa.2002.124913; PMID: 12152163
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405 - 16; http://dx.doi.org/10.1021/jm800483v; PMID: 18989950
   PubMed Web of Science ®Google Scholar
• Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935 - 44; http://dx.doi.org/10.1158/0008-5472.CAN-07-5155; PMID: 18339875
   PubMed Web of Science ®Google Scholar
• Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282:14845 - 52; http://dx.doi.org/10.1074/jbc.M606695200; PMID: 17395594
   PubMed Web of Science ®Google Scholar
• Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2010; 19:777 - 88; http://dx.doi.org/10.1517/13543784.2010.489548; PMID: 20465362
   PubMed Web of Science ®Google Scholar
• Jones SF, Moore KN, Patel MR, Infante JR, Poli A, Keegan M, Burris HA. A phase I/IB study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer. J Clin Oncol [Online] 2013; suppl; abstr TPS2620. Available from: http://meetinglibrary.asco.org/content/117259-132
   Google Scholar
• Hirt U, , Schleicher M, et al. BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer. Mol Can Ther 2011; 10; http://dx.doi.org/10.1158/1535-7163.TARG-11-A249
   Google Scholar
• Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) 2014; 19:687 - 706; http://dx.doi.org/10.2741/4236; PMID: 24389213
   PubMed Web of Science ®Google Scholar
• Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 2005; 169:941 - 52; http://dx.doi.org/10.1083/jcb.200411155; PMID: 15967814
   PubMed Web of Science ®Google Scholar
• Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2010; 2:516 - 28; http://dx.doi.org/10.1002/emmm.201000106; PMID: 21154724
   PubMed Web of Science ®Google Scholar
• Gadducci A, Ferrero A, Cosio S, Zola P, Viacava P, Dompé D, Fanelli G, Ravarino N, Motta M, Cristofani R, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res 2006; 26:5B 3925 - 32; PMID: 17094423
   PubMedGoogle Scholar
• Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol 2007; 26:395 - 403; http://dx.doi.org/10.1097/pgp.0b013e318063bed7; PMID: 17885489
   PubMed Web of Science ®Google Scholar
• Agochiya M, Brunton VG, Owens DW, Parkinson EK, Paraskeva C, Keith WN, Frame MC. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999; 18:5646 - 53; http://dx.doi.org/10.1038/sj.onc.1202957; PMID: 10523844
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Kaur A, Cance W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta 2004; 1678:111 - 25; http://dx.doi.org/10.1016/j.bbaexp.2004.03.002; PMID: 15157737
   PubMed Web of Science ®Google Scholar
• Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA 3rd, Miller DS, Mathis JM. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995; 59:171 - 8; http://dx.doi.org/10.1006/gyno.1995.0002; PMID: 7590467
   PubMed Web of Science ®Google Scholar
• Brower V. Ovarian cancer genome sequencing unveils findings. J Natl Cancer Inst 2011; 103:1288 - 90; http://dx.doi.org/10.1093/jnci/djr346; PMID: 21852263
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1999; 274:20693 - 703; http://dx.doi.org/10.1074/jbc.274.29.20693; PMID: 10400703
   PubMed Web of Science ®Google Scholar
• Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001; 158:2097 - 106; http://dx.doi.org/10.1016/S0002-9440(10)64681-0; PMID: 11395387
   PubMed Web of Science ®Google Scholar
• Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010; 14:77 - 94; http://dx.doi.org/10.1517/14728220903460340; PMID: 20001212
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 2010; 10:735 - 41; http://dx.doi.org/10.2174/187152010794728648; PMID: 21214510
   PubMed Web of Science ®Google Scholar
• Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D’Angelica MI, Barakat RR, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006; 103:1083 - 90; http://dx.doi.org/10.1016/j.ygyno.2006.06.028; PMID: 16890277
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122:521 - 6; http://dx.doi.org/10.1016/j.ygyno.2011.04.041; PMID: 21683993
   PubMed Web of Science ®Google Scholar
• Halder J, Landen CN Jr., Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005; 11:8829 - 36; http://dx.doi.org/10.1158/1078-0432.CCR-05-1728; PMID: 16361572
   PubMed Web of Science ®Google Scholar
• Halder J, Kamat AA, Landen CN Jr., Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006; 12:4916 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-06-0021; PMID: 16914580
   PubMed Web of Science ®Google Scholar
• Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 2012; 30:1527 - 33; http://dx.doi.org/10.1200/JCO.2011.38.9346; PMID: 22454420
   PubMed Web of Science ®Google Scholar
• Sood AK, Coleman RL, Ellis LM. Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer. J Clin Oncol 2012; 30:345 - 7; http://dx.doi.org/10.1200/JCO.2011.38.8413; PMID: 22184398
   PubMed Web of Science ®Google Scholar
• Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013; 4:2427; http://dx.doi.org/10.1038/ncomms3427; PMID: 24018975
   PubMed Web of Science ®Google Scholar
• Bikfalvi A, Moenner M, Javerzat S, North S, Hagedorn M. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans 2011; 39:1560 - 4; http://dx.doi.org/10.1042/BST20110710; PMID: 22103487
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15:5020 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-09-0095; PMID: 19671869
   PubMed Web of Science ®Google Scholar
• Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007; 109:332 - 40; http://dx.doi.org/10.1002/cncr.22415; PMID: 17154180
   PubMed Web of Science ®Google Scholar
• Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-06-3700; PMID: 17308118
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med 2005; 202:941 - 53; http://dx.doi.org/10.1084/jem.20050128; PMID: 16203865
   PubMed Web of Science ®Google Scholar
• Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004; 5:557 - 72; http://dx.doi.org/10.1093/biostatistics/kxh008; PMID: 15475419
   PubMed Web of Science ®Google Scholar
• Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007; 23:657 - 63; http://dx.doi.org/10.1093/bioinformatics/btl646; PMID: 17234643
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249 - 64; http://dx.doi.org/10.1093/biostatistics/4.2.249; PMID: 12925520
   PubMed Web of Science ®Google Scholar
• Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graph Stat 1996; 5:299 - 314
   Google Scholar
• Leisch F. Compstat 2002 - Proceedings in Computational Statistics. Physica Verlag, Heidelberg, 2002.
   Google Scholar
• Kamat AA, Kim TJ, Landen CN Jr., Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67:281 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-3282; PMID: 17210709
   PubMed Web of Science ®Google Scholar
• Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158:1279 - 88; http://dx.doi.org/10.1016/S0002-9440(10)64079-5; PMID: 11290546
   PubMed Web of Science ®Google Scholar
• Takahashi M, Berk BC. Mitogen-activated protein kinase (ERK1/2) activation by shear stress and adhesion in endothelial cells. Essential role for a herbimycin-sensitive kinase. J Clin Invest 1996; 98:2623 - 31; http://dx.doi.org/10.1172/JCI119083; PMID: 8958227
   PubMed Web of Science ®Google Scholar
• Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67:10976 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-07-2667; PMID: 18006843
   PubMed Web of Science ®Google Scholar
• Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010; 285:35462 - 70; http://dx.doi.org/10.1074/jbc.M110.109579; PMID: 20826776
   PubMed Web of Science ®Google Scholar